平特五不中

Home

Nir Hilzenrat

Academic title(s): 

Associate Professor, 平特五不中

Nir Hilzenrat
Contact Information
Address: 

Jewish General Hospital

3755 Chemin de la C么te-Sainte-Catherine, Montr茅al, Quebec, H3T 1E2

Position: 
Staff member as Gastroenterologist and the Head of the Liver Diseases clinic, Jewish General Hospital, 平特五不中
Degree(s): 

MD

Fellowship Training: 

Gastroenterology; 平特五不中

Areas of expertise: 

Internal Medicine, Gastroenterology & Hepatology

Biography: 

Dr. Nir Hilzenrat joined Montreal鈥檚 Jewish General Hospital in 2001 as a gastroenterologist and the head of the hospital鈥檚 liver diseases clinic. As an Associate Professor in Medicine, Dr. Hilzenrat has also focused on teaching medical students and residents at 平特五不中.

Dr. Hilzenrat graduated from the Faculty of Medicine in the Technion Institute of Technology, Israel鈥檚 preeminent medical school. He attained his degree as a Specialist in Internal Medicine following a residency at Ben-Gurion University in Israel. He completed his Specialty in Gastroenterology following a 2-year fellowship at 平特五不中 in Montreal. Prior to joining the Jewish General Hospital, Dr. Hilzenrat was the head of liver diseases services at Ben-Gurion University鈥檚 Soroka Medical Centre, where he also carried on a busy gastroenterology practice.

Dr. Hilzenrat has authored numerous publications in professional journals or chapters medical books. He has also been the Principal Investigator for over 20 national and international clinical trials, assisting in the development of innovative treatments for HCV and HBV. He is also a member of several professional associations, including the CASL (former Councillor on CASL鈥檚 Governing Board), CAG, AASLD, AGA and EASL.

Selected publications: 
  1. Hilzenrat N, Lamoureux E, Szilagyi A. Fatty Liver Disease. In: A.B.R. Thomson and E.A. Shaffer (eds.): First Principles of Gastroenterology and Hepatology, CAPstone Academic Publishers Ltd. Pp 413-424, 2012.
  2. Al-Busafi S, McNabb-Baltar J, Farag A, Hilzenrat N. Clinical Manifestations of Portal Hypertension. International Journal of Hepatology, vol. 2012.Article ID 203794, 10 pages, 2012. doi:10.1155/2012/203794.( or hindawi.com/journals/ijhep/2012/203794/)
  3. Cooper C, Shafran S, Greenbloom S, R Enns, Farley J, Hilzenrat N, Williams K, Elkashab M, Abadir N and Neuman M. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy. Canadian Journal of Gastroenterology and Hepatology; 28: 35- 40. 2014
  4. Bhat M, Wyse J.M, Moodie E, Ghali P, Hilzenrat N, Wong P and Deschenes M.Prevalence and predictors of sleep disturbance among liver diseases in long-term transplant survivors. Canadian Journal of Gastroenterology, 29: 440-444, 2015
  5. Galiatsatos P, Assouline S, Gologean A and Hilzenrat N. Rituximab-induced autoimmune hepatitis: A case study and literature review. Canadian Livver Journal 2020:3-4: 3(4), 381鈥�386
Location: 
Jewish General Hospital
Back to top